title: Histopathological investigation on salt-loaded stroke-prone spontaneously hypertensive rats, whose biochemical parameters of renal dysfunction were ameliorated by administration of imidapril.
abstract: Our previous studies showed that imidapril prevented the occurrence of cerebral stroke and ameliorated biochemical parameter changes of renal dysfunction at a dose that did not inhibit the progression of hypertension in salt-loaded stroke-prone spontaneously hypertensive rats (SHRSP). To confirm these findings, a histopathological investigation was conducted on the kidney of salt-loaded (from 11 to 16 weeks of age) SHRSP, which was the subject of the preceding study. Their brains and hearts were also examined. Histopathologically, renal lesions such as fibrinoid necrosis and proliferative arteritis of small calibration arteries, necrotizing glomerulitis and tubular degeneration, and cerebral hemorrhage and slight cardial hypertrophy were observed in salt-loaded control SHRSP. The occurrence of these lesions were prevented in a dose-dependent manner by the administration of imidapril (1 and 2 mg/kg/day). Especially, the preventive effects on the renal lesions were apparently noted. Enalapril also prevented these renal lesions, but its preventive effects were weaker than those of imidapril at the same dose (2 mg/kg/day). It became evident from the results of the present and previous studies that imidapril reduced renal biochemical and histopathological injuries.
authors.affiliation: Safety Research Laboratory, Tanabe Seiyaku Co., Ltd., Osaka, Japan.
authors.forename: T
authors.initials: T
authors.lastname: Fujiwara
authors.forename: H
authors.initials: H
authors.lastname: Yuasa
authors.forename: N
authors.initials: N
authors.lastname: Ogiku
authors.forename: Y
authors.initials: Y
authors.lastname: Kawai
mesh_terms: D000818:Animals; D000959:Antihypertensive Agents / Q000008:administration & dosage / Q000494:pharmacology / Q000627:therapeutic use*; D001344:Autopsy; D001488:Basilar Artery / Q000187:drug effects / Q000473:pathology; D001921:Brain / Q000187:drug effects / Q000473:pathology / Q000648:ultrastructure; D002561:Cerebrovascular Disorders / Q000209:etiology / Q000517:prevention & control; D004195:Disease Models, Animal; D004305:Dose-Response Relationship, Drug; D004656:Enalapril / Q000494:pharmacology / Q000627:therapeutic use; D006321:Heart / Q000187:drug effects; D006977:Hypertension, Renal / Q000188:drug therapy* / Q000473:pathology; D007093:Imidazoles / Q000008:administration & dosage / Q000494:pharmacology / Q000627:therapeutic use*; D048289:Imidazolidines; D007668:Kidney / Q000187:drug effects / Q000473:pathology* / Q000648:ultrastructure; D007677:Kidney Function Tests; D007678:Kidney Glomerulus / Q000187:drug effects / Q000473:pathology / Q000648:ultrastructure; D008297:Male; D008856:Microscopy, Fluorescence; D009206:Myocardium / Q000473:pathology / Q000648:ultrastructure; D009929:Organ Size / Q000187:drug effects; D051381:Rats; D011918:Rats, Inbred SHR; D017673:Sodium Chloride, Dietary / Q000008:administration & dosage
chemical_list: D000959:Antihypertensive Agents; D007093:Imidazoles; D048289:Imidazolidines; D017673:Sodium Chloride, Dietary; D004656:Enalapril; C065166:imidapril